


## Clinical Laserthermia Systems

Healthcare  
Sweden


## KEY DATA

Stock country	Sweden
Bloomberg	CLSB SS
Reuters	CLSRb.ST
Share price (close)	SEK 8.46
Free Float	100%
Market cap. (bn)	EUR 0.03/SEK 0.29
Website	<a href="https://clinicallaser.se">https://clinicallaser.se</a>
Next report date	22 Nov 2018

## PERFORMANCE



## VALUATION APPROACH



Source: Nordea estimates

## ESTIMATE CHANGES

Year	2018E	2019E	2020E
Sales	16%	31%	4%
EBIT (adj)	11%	23%	24%

Source: Nordea estimates

## Nordea Markets - Analysts

Hans Mähler  
DirectorDan Johansson  
Analyst

## Enhancing its product offering

Clinical Laserthermia Systems (CLS) reported an operating loss of SEK 15.4m in Q2 this year, in line with expectations, compared to a loss of SEK 5.3m in Q2 2017. The increased loss was largely explained by no recognition of Horizon2020 grants this quarter. Instead, CLS will receive SEK 4m in Q4, upon submitting the final project report in November. Operationally, the company has finalised its three EU studies within the communicated time plan. In addition, two new interesting commercial collaborations with Exact Imaging and Image Guided Therapy have recently been announced.

## Repeat orders serve as proof of concept

In Q2, CLS reported an operating loss of SEK 15.4m, compared with a loss of SEK 5.3m in Q2 2017. The delta compared to last year reflects that no Horizon2020 funds were recognised in Q2 this year, as well as costs related to the equity issue. In June, CLS received another order of single-use accessories for MRI-guided laser ablation from University of Texas Medical Branch; the order value was about SEK 0.4m. In addition, a follow-up order of SEK 0.11m has been received from an unannounced leading US hospital. On 7 August, CLS announced that Desert Medical Imaging chose its TRANBERG system in a clinical trial of MRI-guided FLA in prostate cancer.

## Completion of patient recruitment

On 13 August, CLS reported that recruitment had been finalised for the three clinical studies conducted within the frame of the Horizon2020 project. CEO Lars-Erik Eriksson comments in the report that the company is pleased with the data generated so far and a follow-up of the patients will be finalised during H2. Upon completion, the submission of the project report in November will trigger a Horizon2020 payment of SEK 4m.

## Increasing commercial attractiveness through partnerships

Steps have been taken to increase the attractiveness of the product offering during the past months. First, Exact Imaging and CLS have signed a memorandum to enter into commercial collaboration with the aim to market and sell an optimised product for micro-ultrasound guided FLA treatment in prostate cancer. Second, CLS and Image Guided Therapy are preparing an agreement to develop and commercialise a product for MR-guided temperature monitoring.

## Key triggers are trial outcomes and increased business activity

As the report was largely in line with our expectations, we make only minor changes to our cost estimates. Main triggers for valuation will be the outcomes of clinical trials, as well as signs of increased commercial activity.

## SUMMARY TABLE - KEY FIGURES

SEKm	2014	2015	2016	2017	2018E	2019E	2020E
Total revenue	0	0	4	11	14	20	80
EBITDA (adj)	-18	-17	-27	-21	-25	-31	-18
EBIT (adj)	-18	-17	-27	-21	-25	-32	-22
EBIT (adj) margin	n.m.	n.m.	-736.6%	-185.3%	-178.1%	-160.4%	-27.2%
EPS (adj)	-1.03	-0.82	-1.14	-0.81	-0.75	-0.91	-0.63
EPS (adj) growth	11.5%	20.1%	-39.2%	29.1%	7.4%	-21.9%	30.7%
DPS (ord)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EV/Sales	n.a.	n.a.	n.a.	n.a.	18.9	15.1	3.5
EV/EBIT (adj)	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
P/E (adj)	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
P/BV	n.a.	n.a.	n.a.	n.a.	6.0	17.1	10.2
Dividend yield (ord)	n.a.	n.a.	n.a.	n.a.	0.0%	0.0%	0.0%
FCF Yield bef acq & disp	n.a.	n.a.	n.a.	n.a.	-10.3%	-10.8%	-4.7%
Net debt	-19	-3	-6	-14	-26	5	-14
Net debt/EBITDA	1.1	0.2	0.2	0.7	1.1	-0.2	0.8
ROIC after tax	-107.7%	-87.2%	-151.5%	-108.5%	-94.1%	-109.4%	-92.2%

Source: Company data and Nordea estimates


# Quarterly review

The past few months have been action-packed for Clinical Laserthermia (CLS). In August, the company announced that recruitment has finalised for the trials conducted within the Horizon2020 framework. The interim report will be published in November, which will trigger an additional payout of SEK 4m in research funding to CLS. In addition, CLS has received further repeat orders from the University of Texas Medical Branch, as well as another undisclosed US hospital. On 7 August, CLS also announced that Desert Medical Imaging will use the TRANBERG® in a clinical trial with MR-guided FLA in prostate cancer. Lastly, two new initiatives for entering into commercial cooperation and broadening the product offering have been communicated.

Increased costs mainly explained by one-off items


In line with expectations, Clinical Laserthermia Systems (CLS) reported an operating loss of SEK 15.4m in Q2, compared with a loss of SEK 5.3m in the same period last year. This is partly impacted by the fact that no Horizon2020 funds were recognised this quarter. The company will receive SEK 4m in November, however, upon submitting the final project report. The company raised SEK 49m before transaction costs, which will provide the means to increase commercial activity and technical development.

QUARTERLY REVENUE



Source: Company data and Nordea estimates

QUARTERLY OPERATING COSTS



Source: Company data and Nordea estimates

Horizon2020 trials completed; interim results expected in November

### Interim report to be published in November

In August, CLS announced that, in line with previous communication, recruitment has been finalised for the three ongoing clinical trials within the Horizon2020 framework. In total, CLS was granted EUR 2.1m from the EU programme for research and innovation in the project that started during 2016. The study has been conducted at three hospitals: Institut Paoli-Calmettes in France (pancreatic cancer), Portuguese Institute of Oncology in Portugal (pancreatic cancer) and Nottingham University Hospital in England (breast cancer). CLS said it is satisfied with the results received regarding safety and the implementation of imILT so far. A followup of treatments will be conducted in the coming months upon submission of the interim report to the EU in November. Upon completion, CLS will receive SEK 4m.

CLS to receive SEK 4m upon submitting project report

### Repeat orders support value proposition

Two repeat orders received during the summer

On 28 June, the University Of Texas Medical Branch (UTMB) placed a new order for CLS's sterile single-use products, relating to MRI-guided focal laser ablation. The supplier agreement with UTMB was entered in October last year. Thereafter, UTMB has made additional orders for single-use products. It also bought a Mobile Laser Unit and can now work with a complete TRANBERG | Thermal Therapy System. Through its repeat orders, the university has become an important reference for CLS in the US. The latest order value amounts to about SEK 0.4m.

In addition, the undisclosed leading hospital in the US, with which CLS entered a supplier agreement with last year, has booked another order in the beginning of July. According to CLS, the hospital is a regular user of the TRANBERG products for the treatment of vascular malformation and the company maintains strong relations to its

doctors. These malformations are often difficult to diagnose and therefore market estimates vary, but according to US market studies suggests up to ~500,000 new cases every year. The latest order value amounts to about SEK 0.1m.

Small financial impact but positive validation of the concept

Although the financial impact from the two orders was small, we still find it comforting that hospitals use the products on a regular basis. This serves as good external validation of the concept. In order for us to take up our numbers and become more optimistic about penetration, we would first like to see commercial sales pick-up further.

Broadening product offering through two new commercial collaborations

**Enhancing commercial offering**

The current challenge faced by CLS is the commercialisation of its products and grabbing the attention of customers in the market. To obtain their interest, the key component is proof of concept through clinical trials. CLS also has recently announced two new commercial collaborations aimed at improving and broadening its offering.


At the beginning of June, CLS and Exact Imaging announced that they had signed a memorandum of understanding to enter a commercial collaboration. Exact Imaging, according to the announcement, is a world leader in high-resolution micro-ultrasound systems, enabling real-time imaging and guided biopsies in the urological market for prostate cancer. The joint mission is to develop a product for use in high resolution micro-ultrasound guided focused laser ablation and to offer an improved solution for image guided focal therapy in localised prostate cancer patients and benign prostatic hyperplasia (BPH).

According to CLS estimates, the market for BPH and localised prostate cancer is approximately 500,000 treatments per year. CLS image guided FLA is currently being tested for treatment of prostate cancer in a study initiated by the Toronto General Hospital. The study was initiated in April 2018 and will follow the patients for 24 months.

The second announcement came in late June, when CLS signed a term sheet with the French company Image Guided Therapy SA (IGT). IGT is a MedTech company based on research from the university in Bordeaux, with products developed for MRI guided minimally invasive cancer treatments. The goal is to jointly develop a software product, bringing improved workflow for the TRANBERG® system and optimal conditions for measuring and controlling temperature in FLA and imILT treatments.

Overall, we view these announcements as small incremental steps that could improve and broaden the customer offering, although it is too early to assign any value before the collaborations are integrated into end-products.

**GLOBAL SALES IN THE PROSTATE CANCER MARKET**



Source: Evaluate and Nordea

TRANBERG to be used in a ph II trial with Desert Medical Imaging

### Desert Medical Image to include TRANBERG in ph II trial

On 7 August, CLS announced that the TRANBERG® Thermal Therapy System will be used in a Phase II study by Desert Medical Imaging (DMI), a pioneer and visionary in the advanced, minimally invasive treatment of prostate cancer utilising MRI-guided focal laser ablation therapy.

DMI developed its approach in 2010. The procedure involves placing the patient inside the MRI scanner and displaying MRI images and thermal maps on a computer screen. A thin laser fibre is guided to the tumour and laser energy is applied to heat, coagulate and kill the cancer cells. The temperature and extent of the ablation zone are constantly monitored with MRI, which allows for very low side effects.

#### MRI GUIDED BIOPSY



Source: Desert Medical Imaging

The study in which CLS is involved aims to study prostate ablation in patients with localised prostate cancer and obtain information about the efficacy of transrectally delivered, MRI-guided laser focal therapy using real-time MR thermometry in an outpatient setting.

DMI stated in the press release that it chose the TRANBERG® system to be part of the study due to its proven performance with regards to safety, ease of use and effectiveness. In our view, this provides another positive recognition of the concept.

### Estimate changes and valuation triggers

Backed by the SEK 49m equity issue before the summer, CLS has been provided with ample headroom to increase commercial activity. During the fall, we would like to see the company take further steps towards its long-term ambitions, which leaves room for valuation upside if we see more tangible signs that the long-term potential could crystallise.

Equity issue has provided funds to increase commercial activity

Proof of concept through clinical trials and increased customer attention are key valuation triggers

Although ramping up commercial activities is a slow process, we would like to see further repeat orders and potentially orders from new hospitals. Clinical trials and further proof of concept will also be key factors, with the interim results from the EU study coming up in November. Overall, we view it as positive that there are signs of more commercial activity in the past few months. For now, however, we leave our estimates largely unchanged and expect to gain more visibility during H2.

# Detailed estimates

## QUARTERLY NUMBERS

	Q1 2018	Q2 2018	Q3 2018E	Q4 2018E	2018E
<b>Net sales</b>	<b>0.4</b>	<b>0.8</b>	<b>0.5</b>	<b>0.9</b>	<b>2.6</b>
Other operating income	6.1	0.3	0.4	4.7	11.5
<b>Income</b>	<b>6.5</b>	<b>1.1</b>	<b>0.9</b>	<b>5.6</b>	<b>14.1</b>
COGS	-0.4	-0.6	-0.2	-0.4	-1.7
<b>Gross Profit</b>	<b>6.1</b>	<b>0.5</b>	<b>0.7</b>	<b>5.1</b>	<b>12.4</b>
OPEX	-7.4	-15.8	-7.0	-7.0	-37.3
Depreciation and amortisation	0.0	0.0	-0.1	-0.1	-0.3
Other operating expenses	0.0	-0.3	0.0	0.0	-0.3
<b>Operating profit/loss</b>	<b>-1.4</b>	<b>-15.4</b>	<b>-6.4</b>	<b>-2.0</b>	<b>-25.1</b>
Net financials	0.4	0.4	0.3	0.3	1.4
<b>Loss before tax</b>	<b>-1.0</b>	<b>-15.0</b>	<b>-6.1</b>	<b>-1.6</b>	<b>-23.7</b>
Tax	0.0	0.0	0.0	0.0	0.0
<b>Loss for the period</b>	<b>-1.0</b>	<b>-15.0</b>	<b>-6.1</b>	<b>-1.6</b>	<b>-23.7</b>

Source: Company data and Nordea estimates

# Reported numbers and forecasts

## INCOME STATEMENT

SEKm	2010	2011	2012	2013	2014	2015	2016	2017	2018E	2019E	2020E
<b>Net revenue</b>	n.a.	n.a.	0	0	0	0	4	11	14	20	80
Revenue growth	n.a.	n.a.	n.a.	-90.3%	-56.3%	n.m.	n.m.	208.5%	25.3%	39.6%	308.2%
of which organic	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
of which FX	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBITDA	0	0	-13	-18	-18	-17	-27	-21	-25	-31	-18
Depreciation and impairments PPE	0	0	0	0	0	0	0	0	0	0	-2
EBITA	0	0	-13	-18	-18	-17	-27	-21	-25	-31	-20
Amortisation and impairments	0	0	0	0	0	0	0	0	0	-1	-2
EBIT	n.a.	n.a.	-13	-18	-18	-17	-27	-21	-25	-32	-22
of which associates	0	0	0	0	0	0	0	0	0	0	0
Associates excluded from EBIT	0	0	0	0	0	0	0	0	0	0	0
Net financials	0	0	0	0	0	0	0	0	1	0	0
<b>Pre-tax profit</b>	0	0	-13	-18	-17	-17	-27	-21	-24	-32	-22
Reported taxes	0	0	0	0	0	0	0	0	0	0	0
Net profit from continued operations	0	0	-13	-18	-17	-17	-27	-21	-24	-32	-22
Discontinued operations	0	0	0	0	0	0	0	0	0	0	0
Minority interests	0	0	0	0	0	0	0	0	0	0	0
Net profit to equity	0	0	-13	-18	-17	-17	-27	-21	-24	-32	-22
<b>EPS</b>	n.a.	n.a.	-0.87	-1.16	-1.03	-0.82	-1.14	-0.81	-0.75	-0.91	-0.63
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

## Profit margin in percent

EBITDA	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	-735.1%	-183.7%	-176.2%	-155.4%	-22.2%
EBITA	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-176.6%	-157.4%	-24.2%
EBIT	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-178.1%	-160.4%	-27.2%

## Adjusted earnings

EBITDA (adj)	0	0	-13	-18	-18	-17	-27	-21	-25	-31	-18
EBITA (adj)	0	0	-13	-18	-18	-17	-27	-21	-25	-31	-20
EBIT (adj)	0	0	-13	-18	-18	-17	-27	-21	-25	-32	-22
EPS (adj)	n.a.	n.a.	-0.87	-1.16	-1.03	-0.82	-1.14	-0.81	-0.75	-0.91	-0.63

## Adjusted profit margins in percent

EBITDA (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	-735.1%	-183.7%	-176.2%	-155.4%	-22.2%
EBITA (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-176.6%	-157.4%	-24.2%
EBIT (adj)	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	-736.6%	-185.3%	-178.1%	-160.4%	-27.2%

## Performance metrics

<b>CAGR last 5 years</b>											
Net revenue	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	146.8%	311.3%	418.8%	269.0%
EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.
EPS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.
DPS	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
<b>Average last 5 years</b>											
Average EBIT margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-2,352.1%	-665.0%	-367.2%	-247.9%	-97.9%
Average EBITDA margin	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-2,341.9%	-661.9%	-365.2%	-244.8%	-93.6%

## VALUATION RATIOS - ADJUSTED EARNINGS

SEKm	2010	2011	2012	2013	2014	2015	2016	2017	2018E	2019E	2020E
P/E (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
EV/EBITDA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
EV/EBITA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
EV/EBIT (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.

## VALUATION RATIOS - REPORTED EARNINGS

SEKm	2010	2011	2012	2013	2014	2015	2016	2017	2018E	2019E	2020E
P/E	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
EV/Sales	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	18.9	15.1	3.5
EV/EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
EV/EBITA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
EV/EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
Dividend yield (ord.)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	0.0%	0.0%	0.0%
FCF yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-10.3%	-10.8%	-4.7%
Payout ratio	n.a.	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Company data and Nordea estimates

**BALANCE SHEET**

SEKm	2010	2011	2012	2013	2014	2015	2016	2017	2018E	2019E	2020E
Intangible assets	0	0	12	14	17	18	20	24	25	26	29
of which R&D	0	0	0	0	0	0	0	0	0	0	0
of which other intangibles	0	0	12	14	17	18	20	24	25	26	29
of which goodwill	0	0	0	0	0	0	0	0	0	0	0
Tangible assets	0	0	0	0	0	0	0	1	1	1	1
Shares associates	0	0	0	0	0	0	0	0	0	0	0
Interest bearing assets	0	0	0	0	0	0	0	0	0	0	0
Deferred tax assets	0	0	0	0	0	0	0	0	0	0	0
Other non-IB non-current assets	0	0	0	0	0	0	0	0	0	0	0
Other non-current assets	0	0	0	0	0	0	0	0	0	0	0
Total non-current assets	0	0	12	14	17	19	20	25	26	27	30
Inventory	0	0	0	0	0	0	0	3	4	6	23
Accounts receivable	0	0	0	0	0	0	0	0	1	2	12
Other current assets	0	0	1	1	2	1	1	1	2	2	9
Cash and bank	0	0	7	14	19	3	6	16	28	1	21
Total current assets	0	0	8	15	20	4	7	20	35	11	65
Assets held for sale	0	0	0	0	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
<b>Total assets</b>	<b>0</b>	<b>0</b>	<b>20</b>	<b>29</b>	<b>37</b>	<b>22</b>	<b>27</b>	<b>45</b>	<b>61</b>	<b>38</b>	<b>95</b>
Shareholders equity	0	0	17	26	32	19	17	33	49	17	29
Of which preferred stocks	0	0	0	0	0	0	0	0	0	0	0
Of which equity part of hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Minority interest	0	0	0	0	0	0	0	0	0	0	0
Total Equity	0	0	17	26	32	19	17	33	49	17	29
Deferred tax	0	0	0	0	0	0	0	0	0	0	0
Long term interest bearing debt	0	0	0	0	0	0	0	1	2	7	6
Pension provisions	0	0	0	0	0	0	0	0	0	0	0
Other long-term provisions	0	0	0	0	0	0	0	0	0	0	0
Other long-term liabilities	0	0	0	0	0	0	0	0	0	0	0
Convertible debt	0	0	0	0	0	0	0	0	0	0	0
Shareholder debt	0	0	0	0	0	0	0	0	0	0	0
Hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Total non-current liabilities	0	0	0	0	0	0	0	1	2	7	6
Short-term provisions	0	0	0	0	0	0	0	0	0	0	0
Accounts payable	0	0	2	2	4	2	3	3	3	5	20
Other current liabilities	0	0	1	1	1	1	7	7	7	10	40
Short term interest bearing debt	0	0	0	0	0	0	0	0	0	0	0
Total current liabilities	0	0	3	3	5	3	10	11	11	15	60
Liabilities for assets held for sale	0	0	0	0	0	0	0	0	0	0	0
<b>Total liabilities and equity</b>	<b>0</b>	<b>0</b>	<b>20</b>	<b>29</b>	<b>37</b>	<b>22</b>	<b>27</b>	<b>45</b>	<b>61</b>	<b>38</b>	<b>95</b>
<b>Balance sheet and debt metrics</b>											
Net debt	0	0	-7	-14	-19	-3	-6	-14	-26	5	-14
Working capital	0	0	-2	-2	-4	-2	-9	-5	-3	-4	-16
Invested capital	0	0	10	13	13	17	11	19	23	23	14
Capital employed	0	0	17	26	32	19	17	34	50	24	35
ROE	n.m.	n.m.	-148.6%	-84.9%	-60.7%	-65.0%	-147.6%	-84.9%	-58.1%	-96.0%	-95.9%
ROIC	n.m.	n.m.	-196.0%	-124.5%	-107.7%	-87.2%	-151.5%	-108.5%	-94.1%	-109.4%	-92.2%
ROCE	n.a.	n.a.	-74.2%	-69.6%	-55.7%	-85.3%	-157.6%	-60.7%	-49.9%	-133.3%	-62.6%
Net debt/EBITDA	n.m.	n.m.	0.6	0.7	1.1	0.2	0.2	0.7	1.1	-0.2	0.8
Interest coverage	n.a.	n.a.	-806.7	-99.7	-482.5	-15,743.7	-490.0	-410.4	-659.4	-879.1	-609.1
Equity ratio	n.m.	n.m.	85.2%	89.4%	85.4%	87.4%	62.5%	73.4%	80.1%	44.6%	30.1%
Net gearing	n.m.	n.m.	-40.6%	-51.8%	-59.2%	-13.5%	-36.3%	-41.9%	-53.9%	32.0%	-49.5%

Source: Company data and Nordea estimates

**CASH FLOW STATEMENT**

SEKm	2010	2011	2012	2013	2014	2015	2016	2017	2018E	2019E	2020E
<b>EBITDA (adj) for associates</b>	<b>0</b>	<b>0</b>	<b>-13</b>	<b>-18</b>	<b>-18</b>	<b>-17</b>	<b>-27</b>	<b>-21</b>	<b>-25</b>	<b>-31</b>	<b>-18</b>
Paid taxes	0	0	0	0	0	0	0	0	0	0	0
Net financials	0	0	0	0	0	0	0	0	1	0	0
Change in provisions	0	0	0	0	0	0	0	0	0	0	0
Change in other LT non-IB	0	0	0	0	0	0	0	0	0	0	0
Cash flow to/from associates	0	0	0	0	0	0	0	0	0	0	0
Dividends paid to minorities	0	0	0	0	0	0	0	0	0	0	0
Other adj to reconcile to cash flow	0	0	0	0	0	0	0	0	-3	0	0
<b>Funds from operations (FFO)</b>	<b>0</b>	<b>0</b>	<b>-13</b>	<b>-18</b>	<b>-18</b>	<b>-17</b>	<b>-27</b>	<b>-21</b>	<b>-26</b>	<b>-31</b>	<b>-18</b>
Change in NWC	0	0	1	0	2	-2	7	-3	-2	1	11
<b>Cash flow from operations (CFO)</b>	<b>0</b>	<b>0</b>	<b>-12</b>	<b>-18</b>	<b>-16</b>	<b>-19</b>	<b>-20</b>	<b>-24</b>	<b>-28</b>	<b>-30</b>	<b>-7</b>
Capital expenditure	0	0	-2	-2	-2	-2	-2	-5	-2	-2	-7
<b>Free cash flow before A&amp;D</b>	<b>0</b>	<b>0</b>	<b>-14</b>	<b>-21</b>	<b>-18</b>	<b>-21</b>	<b>-21</b>	<b>-29</b>	<b>-30</b>	<b>-32</b>	<b>-14</b>
Proceeds from sale of assets	0	0	0	0	0	0	0	0	0	0	0
Acquisitions	0	0	0	0	0	0	0	0	0	0	0
Free cash flow	0	0	-14	-21	-18	-21	-21	-29	-30	-32	-14
Dividends paid	0	0	0	0	0	0	0	0	0	0	0
Equity issues / buybacks	0	0	19	27	23	4	25	37	43	0	33
Net change in debt	0	0	0	0	0	0	0	2	0	5	0
Other financing adjustments	0	0	0	0	0	0	0	0	0	0	0
Other non-cash adjustments	0	0	2	0	0	0	0	0	0	0	0
Change in cash	0	0	7	6	5	-16	4	9	12	-27	19

**Cash flow metrics**

Capex/D&A	n.m.	n.m.	1,721.7%	2,099.7%	4,291.7%	3,557.0%	2,889.1%	2,656.0%	631.6%	200.0%	180.0%
Capex/Sales	n.a.	n.a.	-1,672.2%	0,381.9%	1,063.7%	-1,614.2%	-42.2%	-41.5%	-12.0%	-10.0%	-9.0%

**Key information**

Share price year end (/current)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	8	8	8
Market cap.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	293	293	293
Enterprise value	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	266	298	279
Diluted no. of shares, year-end (m)	0.0	0.0	14.6	17.0	17.0	23.4	23.8	28.7	34.6	34.6	34.6

Source: Company data and Nordea estimates



**Disclaimer and legal disclosures****Origin of the report**

This report originates from: Nordea Bank AB (publ), including its branches Nordea Danmark, filial af Nordea Bank AB (publ), Sverige, Nordea Bank AB (publ), filial i Finland and Nordea Bank AB (publ), filial i Norge (together "Nordea") acting through their unit Nordea Markets.

Nordea Bank AB (publ) is supervised by the Swedish Financial Supervisory Authority and the branches are supervised by the Swedish Financial Supervisory Authority and the Financial Supervisory Authorities in their respective countries.

**Content of report**

This report has been prepared solely by Nordea Markets.

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

**Validity of the report**

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

**No individual investment or tax advice**

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any relevant jurisdiction.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

**Sources**

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from: Nordea Markets' analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets ("External Information"), Nordea Markets has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

**Limitation of liability**

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

**Risk information**

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

**Conflicts of interest**

Readers of this document should note that Nordea Markets has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report.

Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea Markets that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at [www.nordea.com/mifid](http://www.nordea.com/mifid).

**Distribution restrictions**

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US. This research report is intended only for, and may be distributed only to, accredited investors, expert investors or institutional investors in Singapore who may contact Nordea Bank, Singapore Branch of 3 Anson Road, #22-01, Springleaf Tower, Singapore 079909.

This report may be distributed by Nordea Bank Luxembourg S.A., 562 rue de Neudorf, L-2015 Luxembourg which is subject to the supervision of the Commission de Surveillance du Secteur Financier.

This report may be distributed by Nordea Bank, Singapore Branch, which is subject to the supervision of the Monetary Authority of Singapore.

This report may be distributed in the UK to institutional investors by Nordea Bank AB, London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is authorised by Finansinspektionen (Financial Supervisory Authority) in Sweden and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws.

**Analyst Shareholding**

Nordea Markets analysts do not hold shares in the companies that they cover. No holdings or other affiliations by analysts or associates.

**Fair value sensitivity**

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. When applicable, we set a 12-month target price by applying an appropriate premium/discount and/or other relevant adjustment to our fair value to reflect the share price potential we see within the coming 12 months. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of capital are typically the most sensitive.

It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. Dividend payouts are included in the target price. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

**Marketing Material**

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

Where applicable, recommendation changes are available at: <https://research.nordea.com/compliance#equity-changes>.

**Market-making obligations and other significant financial interest**

Nordea Markets has no market-making obligations in Clinical Laserthermia Systems.

**Investment banking transactions**

In view of Nordea's position in its markets readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services to the company/companies

**Issuer Review**

*This report has not been reviewed by the Issuer prior to publication.*

**Completion Date**

29 Aug 2018, 09:29 CET

Nordea Bank AB (publ)	Nordea Danmark, filial af Nordea Bank AB (publ) Sverige	Nordea Bank AB (publ), filial i Finland	Nordea Bank AB (publ), filial i Norge
<b>Nordea Markets Division, Equities</b>	<b>Nordea Markets Division, Equities</b>	<b>Nordea Markets Division, Equities</b>	<b>Nordea Markets Division, Equities</b>
Visiting address: Smålandsgatan 15 SE-105 71 Stockholm Sweden	Visiting address: Grønjordsvej 10 2300 Copenhagen S Denmark	Visiting address: Aleksis Kiven katu 7, Helsinki FI-00020 Nordea Finland	Visiting address: Essendropsgate 7 N-0107 Oslo Norway
Tel: +46 8 614 7000 Fax: +46 8 534 911 60	Tel: +45 3333 3333 Fax: +45 3333 1520	Tel: +358 9 1651 Fax: +358 9 165 59710	Tel: +47 2248 5000 Fax: +47 2256 8650
Reg.no. 516406-0120 Smålandsgatan 17 Stockholm			